KRAS and ganglioglioma: Additionally, no mutations previously described in gangliogliomas were detected in BRAF, KRAS, FGFR1-3, or H3F3A. Furthermore, there was no evidence of mutations associated with high-grade gliomas, such as TERT, EGFR, TP53, or H3F3A. To exclude rare mutations in NF1, PTPN11, or other genes described in gangliogliomas, we performed an additional analysis using a customized enrichment/hybrid-capture-based panel of genes recurrently altered in brain tumors [11] (Supplementary Material 1).